Univest
Univest
  • Markets

Laurus Labs (LAURUSLABS) Share Price Touches Fresh 52-Week High of Rs 2,177.05

  • September 9, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Laurus Labs Share Price
Laurus Labs Ltd. (LAURUSLABS) share price reached a fresh 52-week high of Rs 2,177.05 today and later stood at Rs 2,172.25, up 1.52% from the previous close. Market cap was Rs 1,11,304.32 crore.

Laurus Labs Share Price is Rs 2,172.25 as of 28 October 2026 at 9:52 AM IST, up 1.52% from the previous close of Rs 2,139.8, after the stock touched a fresh 52-week high of Rs 2,177.05 in early trade. The company has a market capitalisation of Rs 1,11,304.32 crore and sits in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

The Laurus Labs 52-week high was set during the current session. Univest figures confirm the price action, but they do not point to a specific company trigger. What the numbers do show is a stock that opened at Rs 2,144.35 and has so far moved between Rs 2,136.2 and Rs 2,177.05.

Table of Contents

Toggle
  • Laurus Labs Share Price Today: Price Action Analysis
  • Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Laurus Labs
  • About Laurus Labs
  • Frequently Asked Questions
    • What is the Laurus Labs share price today?
    • What is the Laurus Labs 52-week high?
    • Why is the Laurus Labs share price rising today?
    • What is the market cap of Laurus Labs?
    • What is the P/E ratio of Laurus Labs compared with its industry?
    • What are the ROE and ROCE of Laurus Labs?
    • What are the EPS, book value and dividend yield of Laurus Labs?
    • How does Laurus Labs compare with its listed peers?
  • Track Laurus Labs Share Price on Univest

Laurus Labs Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 2,172.25
Previous Close Rs 2,139.8
Today's Move +Rs 32.45 (+1.52%)
Open Rs 2,144.35
High Rs 2,177.05
Low Rs 2,136.2
Market Capitalisation Rs 1,11,304.32 crore

Readers following Laurus Labs Stock News can watch three things next: how the price behaves against the Rs 2,177.05 high, the valuation multiples covered below, and the latest quarterly revenue of Rs 2,026.31 crore for Jun 2026. Univest brings the Laurus Labs Share Price Today update together with sector and peer figures in the sections that follow.

Laurus Labs Ltd. (LAURUSLABS) traded at Rs 2,172.25 versus the previous close of Rs 2,139.8, a rise of 1.52%. The stock opened at Rs 2,144.35, reached a high of Rs 2,177.05 and touched a low of Rs 2,136.2.

What happened to Laurus Labs today? The stock touched a fresh 52-week high of Rs 2,177.05 and is trading at Rs 2,172.25, a gain of Rs 32.45 or 1.52% over the previous close of Rs 2,139.8. The Laurus Labs Share Price opened at Rs 2,144.35 and has so far moved between Rs 2,136.2 and Rs 2,177.05.

The gap between the current price and the session high is small. Laurus Labs last traded at Rs 2,172.25 against a day high of Rs 2,177.05, which is also the fresh 52-week high, so the stock stands just below its one-year peak at the time of writing. The day low of Rs 2,136.2 sits slightly below the previous close of Rs 2,139.8, so the range for the session has covered both sides of yesterday’s level.

In the Indian stock market today, this places Laurus Labs among the 52 week high stocks of the session. The event is intraday, so the high of Rs 2,177.05 can change if the stock trades higher before the session ends.

A fresh 52-week high describes where the price stands relative to the last year of trading. It does not, on its own, explain why the move happened, and this article does not offer a reason that the facts do not state. Valuation and earnings context follows in the next section.

Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis

Metric Value
Market Capitalisation Rs 1,11,304.32 crore
P/E Ratio 105.74x
P/B Ratio 20.5x
ROE 18.31%
ROCE 18.2%
EPS Rs 20.24
Book Value Per Share Rs 104.37
Dividend Yield 0.09%

Laurus Labs Ltd. (LAURUSLABS) fundamental metrics show P/E 105.74x, P/B 20.5x, ROE 18.31%, ROCE 18.2%. Taken on their own, these numbers offer context rather than a trading signal.

Laurus Labs Ltd. has a market capitalisation of Rs 1,11,304.32 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 105.74x, P/B at 20.5x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.31% and ROCE of 18.2%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 20.24, book value per share of Rs 104.37, dividend yield of 0.09%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.26x, median ROE of 11.22%, median ROCE of 13.1%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 105.74x
Benchmark Median P/E 30.26x
Benchmark Average P/E 42.93x
Benchmark P/E Range 3.21x to 577.05x
Company P/B Ratio 20.5x
Benchmark Median P/B 2.71x
Company ROE 18.31%
Benchmark Median ROE 11.22%
Company ROCE 18.2%
Benchmark Median ROCE 13.1%
Company Market Capitalisation Rs 1,11,304.32 crore
Benchmark Median Market Cap Rs 692.28 crore

Laurus Labs Ltd. (LAURUSLABS) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 105.74x, which is above the benchmark median of 30.26x, a difference of +249.44%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Laurus Labs Ltd. (LAURUSLABS) has a ROE of 18.31%, which is above the benchmark median of 11.22%, a difference of +63.19%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of 18.2%, which is above the benchmark median of 13.1%, a difference of +38.93%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Cipla Ltd. CIPLA 1,09,304.89 37.65 3.1 11.83 16
Dr. Reddy's Laboratories Ltd. DRREDDY 1,08,758.84 38.9 2.81 11.69 13.75
Zydus Lifesciences Ltd. ZYDUSLIFE 1,15,520.92 25.79 4.32 19.69 21.39
Mankind Pharma Ltd. MANKIND 95,082.98 46.06 5.87 12.69 13.24
Aurobindo Pharma Ltd. AUROPHARMA 91,485.09 25.31 2.41 9.93 12.76

Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 105.74x compared with the displayed peer median of 37.65x. The comparison is relative and should not be read as a recommendation. Its ROE of 18.31% compares with a peer median of 11.83% across the companies shown in the table. ROCE stood at 18.2% versus the displayed peer median of 13.75%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 1,11,304.32 crore. Among the 5 peers shown, 1 has a larger market capitalisation.

Why Investors Are Watching Laurus Labs

  • The stock touched a fresh 52-week high of Rs 2,177.05 today and trades at Rs 2,172.25.
  • The share price is up 1.52% from the previous close of Rs 2,139.8.
  • Market capitalisation of Rs 1,11,304.32 crore is second among the five peers listed.
  • ROE of 18.31% and ROCE of 18.2% are above industry medians of 11.22% and 13.1%.
  • The P/E of 105.74 compares with an industry median of 30.26, and latest quarterly revenue is Rs 2,026.31 crore for Jun 2026.

About Laurus Labs

Laurus Labs Ltd. trades under the symbol LAURUSLABS. Univest classifies it in the Healthcare sector and the Pharmaceuticals & Drugs industry. The latest quarterly revenue stands at Rs 2,026.31 crore for Jun 2026. Readers who want a fuller Laurus Labs company overview can open the stock page on Univest.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What is the Laurus Labs share price today?

Ans. The Laurus Labs Share Price is Rs 2,172.25 as of 28 October 2026 at 9:52 AM IST, up Rs 32.45 or 1.52% from the previous close of Rs 2,139.8, within a day range of Rs 2,136.2 to Rs 2,177.05.

What is the Laurus Labs 52-week high?

Ans. The Laurus Labs 52-week high is Rs 2,177.05, touched today. The stock last traded at Rs 2,172.25, so it sits just below that one-year high while the session is still open and the high can change.

Why is the Laurus Labs share price rising today?

Ans. Univest figures confirm the price action, but they do not point to a specific company trigger. The stock is up 1.52% from the previous close of Rs 2,139.8 and touched a fresh 52-week high of Rs 2,177.05.

What is the market cap of Laurus Labs?

Ans. Laurus Labs has a market capitalisation of Rs 1,11,304.32 crore. Among Cipla, Dr. Reddy's Laboratories, Zydus Lifesciences, Mankind Pharma and Aurobindo Pharma, only Zydus Lifesciences is larger, at Rs 1,15,520.92 crore.

What is the P/E ratio of Laurus Labs compared with its industry?

Ans. The Laurus Labs P/E ratio is 105.74, against an industry median of 30.26 and an average of 42.93 across 169 companies. That places the stock 249.44% above the median P/E for the group.

What are the ROE and ROCE of Laurus Labs?

Ans. Laurus Labs reports ROE of 18.31% and ROCE of 18.2%. Both are above the industry medians of 11.22% for ROE and 13.1% for ROCE, which are drawn from 197 companies in the same industry.

What are the EPS, book value and dividend yield of Laurus Labs?

Ans. EPS is Rs 20.24 and book value per share is Rs 104.37. The dividend yield is 0.09%, which describes the historical payout relative to the current price and is not a guide to future dividends.

How does Laurus Labs compare with its listed peers?

Ans. Laurus Labs has a higher P/E of 105.74 and P/B of 20.5 than Cipla, Dr. Reddy's Laboratories, Zydus Lifesciences, Mankind Pharma and Aurobindo Pharma. Only Zydus Lifesciences reports higher ROE and ROCE in this group.

Track Laurus Labs Share Price on Univest

Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Users can track the live Laurus Labs Share Price, fundamental ratios, 52-week levels and market insights on Univest. The Laurus Labs stock page on Univest brings together the P/E ratio, P/B ratio, ROE, ROCE, EPS and book value discussed above, along with sector and peer figures, so the numbers can be checked again as the session moves.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply